Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients

Inclusion Criteria: * The subjects voluntarily joined this study, signed the informed consent form, and exhibited good compliance; * Aged 18 to 80 years old, with an Eastern Cooperative Oncology Group (ECOG) score of 0 to 2, and an expected survival of more than 12 weeks; * Systemic light chain amyloidosis with diagnostic records (i.e., primary light chain amyloidosis); * Presence of measurable lesions; * At least one organ involved; * Have previously received at least one line of systemic treatment, and recurred and progressed after the remission of the last line treatment; * N-terminal pro-B-type natriuretic peptide (NT-proBNP) ≤ 8500 ng/L; * The corresponding organ function conforms to the protocol requirements; * Women of childbearing age should agree to use contraception during the study period and for 6 months after its completion; they must have a negative serum pregnancy test within 7 days before enrollment in the study and must be non-lactating subjects; men should agree to use contraception during the study period and for 6 months after its completion. Exclusion Criteria: * Diagnosed with other types of amyloidosis, active plasma cell leukemia, active multiple myeloma, etc. * Have received allogeneic hematopoietic stem cell transplantation within 1 year prior to the first dose, or have received autologous hematopoietic stem cell transplantation within 12 weeks prior to the first dose; * Previously received treatment with drugs targeting the same target; * Within …